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ABSTRACT
Aim of the study. To determine the prevalence of anti-interferon-β binding (BAb) and neutralising antibodies (NAb), and to 
investigate whether NAb measured by luciferase-based cell assay can predict treatment response in multiple sclerosis (MS) 
patients treated with interferon-β-1b (IFNβ-1b). 
Clinical rationale for the study. A subgroup of IFNβ-treated MS patients develop NAb directed against the drug. The clinical 
significance remains controversial, which could be explained to some extent by technical difficulties in NAb detection and 
quantification. A simple, specific and reproducible test for NAb might help elucidate these uncertainties. 
Materials and methods. Sera from 101 consecutive MS patients initiating treatment with IFNβ-1b were collected at baseline and 
during the first two years, and assessed for BAbNAb with a novel luciferase-based cell assay. Median clinical follow-up lasted 5.1 years. 
Results. BAb were present in 97% and NAb in 88% of the study cohort. Unexpectedly, 92% of patients tested positive for BAb 
and 12.5% for NAb at baseline, before drug exposure. Patients with baseline NAb positivity were more likely to remain free of 
disease activity in the first three years of treatment. When baseline-positive cases were grouped together with those who rema-
ined NAb-negative, and the resulting group was compared to those who became positive after drug exposure, NAb positivity 
was associated with a higher risk of disease activity during the entire follow-up. Direct comparison of BAb/Nab-positive and 
BAb/Nab-negative patients only revealed an association of BAb positivity with more active disease after four years of treatment, 
while NAb failed to predict the outcome. 
Conclusions and clinical implications. Antibodies developed after treatment initiation are associated with a worse outcome. Na-
turally-occurring antibodies appear to predict more benign disease. Their prevalence and specificity require further investigation.
Key words: multiple sclerosis, interferon-beta, neutralising antibodies, treatment outcome
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Introduction
Interferon beta (IFNβ) continues to be commonly used 
as a first-line disease modifying drug (DMD) in relapsing-
-remitting multiple sclerosis (RRMS) patients, but its efficacy 
varies among individual cases. 
In response to IFNβ treatment, a proportion of patients de-
velop either binding (BAb) or neutralising anti-IFN antibodies 
(NAb). IFNβ-1b is thought to be more immunogenic than 
IFNβ-1a, and a subcutaneous route of administration more 
immunogenic than an intramuscular route [1]. BAb appears 
in up to 97% of patients, usually between the third and twelfth 
months of treatment [1]. NAb appears later (6-24 months) and 
less commonly (28–42%) [1–3]. For pegylated IFNβ-1A, NAb 
prevalence has been shown to be below 1% after two years of 
treatment [4].
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The significance of these findings remains controversial. 
There is evidence from clinical trials and open-label obser-
vational studies that NAb in high titres are persistent [5] and 
associated with a  loss of IFN efficacy [2, 6–8]. In fact, NAb 
may be the most common cause for early treatment failure 
in IFNβ-1b-treated patients [9]. In many studies however, 
Nab’s  influence was most apparent in NAb-positive periods 
[3, 10, 11], and a considerable proportion of NAb-positive 
patients revert to a NAb-negative status over time [3, 10], 
with restoration of IFN activity [10]. On the other hand, some 
researchers [8, 12] have observed only sporadic conversion to 
NAb-negativity and worse outcomes in long term follow-ups.
At least in part, these uncertainties stem from the comple-
xity of NAb measurement. All currently used assays are based 
on NAb-mediated inhibition of IFN’s effects on IFN-responsive 
cells. The effect can be observed as protection from the cyto-
pathic effect in a viral challenge, as in cytopathic effect assay, 
a gold standard since 1985 [13], or confirmed via MxA mRNA 
detection [14]. Attempts to design a non-cellular assay have 
thus far been unsuccessful.
A new generation of tests uses growth-arrested cells trans-
fected with luciferase under a selective class-I IFN controlled 
promotor [15]. While this involves live cells, there is no need 
for continuous cell line culture. Currently, two luciferase-based 
tests have been validated and are commercially available [16, 
17], but no long-term follow-up is available with regards to 
their prognostic value.
Clinical rationale for the study
We sought to determine the influence of IFNβ NAb, 
measured by luciferase-based cell assay, on disease activity in 
RRMS patients treated with IFNβ-1b in a long-term prospec-
tive observation, in the hope that their detection could predict 
drug response and so guide treatment decisions.
Materials and methods
Patients
A total of 101 RRMS patients were recruited consecuti-
vely for this study while initiating treatment with IFNβ-1b in 
the setting of the national MS treatment programme at the 
outpatient clinic at Heliodor Swiecicki University Hospital in 
Poznan, Poland, from 2008 to 2013. The study protocol was 
approved by the Ethics Board of Poznan University of Medical 
Sciences. Inclusion criteria were: age ≥ 18 years; diagnosis 
of RRMS according to the 2005 revision of the McDonald 
criteria [18] (all patients also met the 2010 criteria [19]); no 
prior disease modifying treatment; fulfillment of the national 
treatment programme eligibility criteria (Tab. 1); and written 
informed consent for study participation. 
Treatment consisted of interferon beta-1b (Betaferon, n 
= 96, or Extavia, n = 5) 250μg (8 MIU) subcutaneously every 
other day.
Baseline clinical information was obtained: sex, age at 
first relapse, time to second relapse, time to treatment initia-
tion, number of relapses, and EDSS score prior to treatment 
initiation.
Follow up
The follow up spanned the period from 2008 to 2018 and 
consisted of monthly neurological assessments.
In addition, 1.5 Tesla head magnetic resonance imaging 
(MRI, Siemens Avanto, Erlangen, Germany) with a 12-chan-
nel head coil, including T1, T2, FLAIR (Fluid Attenuated 
Inversion Recovery) and PD (Proton Density) sequences, with 
gadolinium contrast administration, was obtained at baseline 
and was repeated each year. For individual indications, spinal 
MRI was performed.
Each year, we recorded the number of relapses, EDSS 
change, and the presence of new T2/FLAIR or enhancing 
lesions in MRI.
Definition of NEDA
Consistently with previous works [20], NEDA was defined 
as no relapses, no disability progression and no MRI activity in 
a given time period. A relapse was defined as the appearance 
or worsening of symptoms applicable to multiple sclerosis, 
with focal neurological abnormality, lasting 24 hours and 
preceded by ≥ 30 days of neurological stability, in the absence 
of infection or fever. Progression was recognised when an 
increase in EDSS occurred and was confirmed after three 
months. The minimal required increase depended on baseline 
EDSS: ≥ 1.5 for a baseline score of 0 ≥ 1.0 for scores ranging 
from 1.0 to 5.0 and ≥ 0.5 for baseline EDSS of ≥ 5.5. New or 
enlarging lesions in T2/FLAIR or contrast enhancing lesions 
were considered as MRI activity.
Sampling
Serum samples were collected prior to treatment initiation 
and again after one, three, six, 12, 24 and 36 months of treat-
ment, then stored at -70oC until further analysis.




We employed a customised indirect ELISA developed 
at the Department of Neurochemistry and Neuropathology, 
Poznan University of Medical Sciences, Poznan, Poland [21]. 
ELISA plates (Nunc, Roskilde, Denmark) were coated 
with Betaferon (Bayer Pharma AG, Germany) diluted in 
0.05M sodium bicarbonate (final concentration: 1 g/mL). The 
plates were incubated at room temperature for 12 hours, then 
washed with phosphate-buffered salt (PBS) with 0.05% (vol 
/ vol) Tween 20. Nonspecific binding sites were blocked with 
1% bovine albumin solution in PBS-0.05% Tween 20 and the 
plates were washed with PBS-0.05% Tween 20 again. Then, the 
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Table 1. National Multiple Sclerosis treatment programme eligibility criteria in Poland 2008–2013  
Criterion 2008 2012
Diagnosis 2005 McDonald criteria and contrast-enhanced head MRI consistent with MS
Disease activity At least two relapses within the past two years not specified
Required score 21 pt 15 pt
Scoring system Age:
16–40 years — 6 pt
40–60 years — 3 pt
over 60 years — 1 pt
Disease duration:
  0–3 years — 6 pt
3–6 years — 3 pt
6–10 years — 2 pt
over 10 years — 1 pt
RRMS with no neurological deficit — 5 pt.
Number of relapses in the last year:
3–4 — 5 pt
1–2 — 4 pt
6–7 — 2 pt
none (less than 1/year) — 1pt
over 7 — 0 pt
EDSS score:
0–2 — 6 pt
2.5–4 — 3 pt
4.5–5 — 2 pt
over 5 — 1 pt 
Disease duration:
  0–3 years — 6 pt
3–6 years — 4 pt
6–10 years — 2 pt
over 10 years — 1 pt
RRMS with no neurological deficit — 5 pt
Number of relapses in the last year:
3 and more — 5 pt
1–2 — 4 pt
none  — 1pt
EDSS score:
0–2 — 6 pt
2.5–4 — 5 pt
4.5–5 — 2 pt
over 5 — 1 pt 
Exclusion criteria 1. hypersensitivity to IFNβ
2. primarily or secondarily progressive MS
3. pregnancy
4. decompensated liver disease (aminotranferase levels ≥ 2x upper reference limit)
5. thyroid disease (no euthyreosis)
6. intractable depressive mood disorder or history of suicidal ideation
7. epilepsy
MRI — magnetic resonance imaging; MS — multiple sclerosis; RRMS —relapsing–remitting multiple sclerosis; pt — points; EDSS — Expanded Disability Status Score
standard and patient sera were added. As standard, we em-
ployed goat anti-human interferon antibodies (Sigma-Aldrich) 
in dilutions of 1:20, 1:50, 1:100, 1:200 and 1: 400. Patient sera 
were assessed at a dilution of 1:100. After incubation at room 
temperature, the plates were washed with PBS-0.05% Tween 
20. Then, secondary antibodies were added (goat anti-rabbit 
IgG and rabbit anti-human IgG conjugated with alkaline pho-
sphatase, Sigma-Aldrich). P-nitrophenyl phosphate was used 
as the alkaline phosphatase substrate (Sigma-Aldrich) and 1 M 
HCl as the inhibitor. Absorbance was measured at wavelength 
= 405 nm with ELx800 ELISA reader (Bio-TEK), as optical 
density, in arbitrary units (AU/ml), following the formula:
(10 × tested sample absorbance) / (cut-off values absorbance)
The cut-off was defined at the absorbance’s 95th percentile. 
A standard curve, based on log-log regression (R2 = 0.978), 
was prepared for the correlation between absorbance and 
reciprocal standard dilution. Reciprocal serum dilutions were 
then read from the standard curve. A standard curve was also 
drawn for correlation between concentration of standard and 
absorbance. 
A patient was considered BAb positive, BAb (+), if BAb 
were detected at any time, and BAb negative, BAb (-), if no 
sample tested positive and at least one was obtained after ≥ 
6 months of treatment. A patient was considered persistently 
BAb (+) if he or she did not revert to BAb (-) in further samples, 
and transient BAb (+) otherwise.
Neutralising antibody detection
To detect NAb, we used a luciferase reporter gene assay 
(iLite® Type I IFN Assay Ready Cells, Euro-Diagnostica, Swe-
den) which involves live cells transfected with luciferase under 
a selective IFN type I-controlled promotor. When exposed to 
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Table 2. Study cohort baseline characteristics; P values for gender difference
All Female Male p
Age at first relapse, years, mean ± SD 29.9 ± 8.7 31.3 ± 9.2 25.7 ± 5.2 < 0.001
Time to second relapse, months, median (IQR) 10.0 (4.0 to 24.25) 10.0 (4.0 to 24.0) 11.5 (4.5 to 31.5) 0.401
Time to treatment initiation, months, median (IQR) 18.0 (12.0 to 35.0) 23.0 (12.0 to 35.0) 16.5 (7.5 to 34.5) 0.294
Relapses before treatment, median (IQR) 2 (2 to 3) 2 (2 to 3) 2 (2 to 3) 0.568
EDSS at baseline, median (IQR) 1.0 (0 to 1.5) 1.0 (0 to 1.5) 1.0 (0 to 1.25) 0.445
OCB in CSF, % positive 94% 95% 93% 1.000
Follow-up duration, years, median (IQR)  5.1 (2.9 to 7.15)  4.7 (2.9 to 6.7) 5.75 (2.9 to 8.25) 0.446
SD — standard deviation; IQR — interquartile range
IFNβ, the cells synthesise luciferase which generates biolumi-
nescence. In the presence of IFN-neutralising antibodies, the 
intensity of luminescence decreases.
We used standard recombinant human IFNβ protein 
(Abcam) and standard positive and negative control sera 
(Euro-Diagnostica).
To inactivate native IFNβ, serum samples were incubated 
at 56°C for 30 minutes. The samples were then diluted with 
the diluent provided (Diluent D): 100 μL for a 60 μL sample. 
Pre-diluted samples and control sera were added to wells on 
a microplate, which were then closed with a  lid, mixed by 
swirling, and left for 30 minutes at 37°C with 5% CO2.
iLite Type I  IFN Assay Ready Cells were thawed in 
a 15-minute 37ºC water bath, then diluted according to the 
manufacturer’s instructions and 50 μL of the cell suspension 
was added to each well. The microplate was mixed and incu-
bated at 37°C with 5% CO2 for 18 hours. Thirty minutes before 
the incubation completion, Bright-Glo™ Luciferase Assay 
System was thawed. The substrate was prepared as instructed 
by the manufacturer and added to each well in 50 μL portions. 
The microplate was mixed and incubated for two minutes in 
darkness at room temperature, then placed in a luminometer 
(FLx800, Bio-TEK). Luminescence intensity was recorded. 
A calibration curve was prepared for the correlation be-
tween light intensity in relative light units (RLU) and standard 
concentration. A sample was considered NAb-positive if the ra-
tio of luminescence intensity of the sample and standard mean 
was ≤ 1.0. If the ratio was >1.0 the sample was labelled negative.
A patient was NAb positive, NAb (+), if NAb were detected 
at any time during follow-up, and NAb negative, NAb (-), if all 
samples, including at least one collected at ≥ 24 months, were 
negative. If a NAb (+) patient did not test negative later, the 
patient was considered to be persistently NAb (+). Otherwise, 
he or she would be labelled transient NAb (+).
Statistical methods
Variables are presented as either mean ± standard de-
viation (SD) for normally distributed variables, or median 
with interquartile range (IQR) for variables without normal 
distribution.
Baseline characteristics were assessed for mutual corre-
lations and compared in subgroups depending on BAb and 
NAb status.
Associations were considered between antibody status 
and the results of the follow-up (NEDA, relapse occurrence, 
disability progression, MRI activity) in each subsequent year, 
for each period up to a given year and after a given year, and 
for the entire follow-up. They were compared between the 
subgroups: BAb (+) and (-), persistent BAb (+) and (-), NAb 
(+) and (-), persistent NAb (+) and (-). 
We used Fisher’s  exact test for nominal variables and 
Mann-Whitney U  test for ordinal variables. For interval 
variables, normality of distribution and equality of variances 
was assessed with d’Agostino-Pearson and Levene’s tests. For 
normally distributed variables, comparisons were made with 
the use of t-test. For non-normal data distribution, Mann-
-Whitney U test was employed instead.
P values of ≤ 0.05 were considered statistically significant.
Statistical analyses were performed using StatSoft STATI-
STICA version 13 [22] and MedCalc, version 15.8 [23].
Results
Baseline
A total of 101 RRMS patients, 77 females and 24 males, 
were recruited for the study. In Table 2, the baseline charac-
teristics of the study cohort are presented. Women were older 
than men. There were no other significant gender-specific 
differences.
Of 101 patients included in the study, nine had com-
pensated thyroid disease, including six with subclinical 
hypothyroidism, one with Hashimoto disease, one with 
non-toxic goitre treated with levothyroxine, and one on 
levothyroxine following thyroidectomy due to toxic goitre. 
Two subjects had asthma, one had a history of uveitis, and 
another one of hepatitis of unknown aetiology (both wit-
hout treatment at the time of our study). Four patients had 
a history of anxiety and/or mood disorders, including one 
who was treated with mirtazapine. In two patients, arterial 
hypertension was present.
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Antibody prevalence
200 samples were included in the final analysis. This allowed 
us to determine BAb status in 97 and NAb status in 77 patients.
Most patients developed both binding and neutralising 
antibodies. Overall, 95 (97%) had at least one BAb (+) sample. 
Of these, seven reverted to BAb (-), making 91% persistently 
BAb (+). Three cases (2%) remained negative throughout the 
entire study. For NAb, 68 (88%) tested positive, and among 
them, one reverted to NAb (-), leaving 87% persistently NAb 
(+). Nine patients (12%) were NAb (-).
The overwhelming majority of patients tested positive for 
BAb at baseline (66 out of 72 sampled = 92%). The patients 
who developed BAb later tested positive between one and 
24 months. Notably, many patients with baseline BAb had 
transient reversal to BAb (-) in the first two years, and became 
BAb (+) again at 24 months.
The prevalence of NAb positivity at baseline was lower: 
nine out of 72 (12.5%) tested positive. An additional three 
patients converted to NAb (+) within the first two years, the 
rest tested positive at 24 months. Of note, few samples were 
collected at baseline and 24 months. 
The summary of antibody prevalence is shown in Tables 3 and 4.
Follow-up
The patients were followed up for a median of 60 months 
(range 4 to 110).
Between 70% and 80% of patients maintained NEDA 
criteria of no disease activity in each year from year 1 to year 
6, 60% in year 7, 70% in year 8, and 60% in year 9 (Fig. 1). 
The cumulative count of patients who maintained NEDA-3 is 
shown in Figure 2.
Discontinuation statistics
A total of 66 patients stopped treatment during the study. 
Twenty-three patients (35%) had their treatment revoked after 
three years because the Polish MS treatment programme was 
limited to three years until 2012. Seven patients (11%) became 
pregnant or were considering doing so. Another seven patients 
resigned for personal reasons. Adverse effects were reasons for 
discontinuation in 14 patients (21%). In 15 cases (23%), the 
drug was switched due to lack of efficacy.
No associations between discontinuation for any reason 
and antibodies or baseline characteristics were found.
Correlations with baseline clinical  
characteristics
Patients with NEDA for the first seven years had fewer 
relapses prior to treatment (p = 0.038). Likewise, fewer pre-
-treatment relapses were reported in patients with no disease 
progression after the first and second years (p = 0.011 and 
0.014), within the first six years (p = 0.023), and at any time du-
ring the observation (p = 0.011). Patients with progression after 
the second year were older at the time of their first relapse (p = 
0.025). Most of the significant differences were in baseline EDSS 
score, which was higher in cases with progression within the 
first two, three, seven and eight years (p ranging from 0.017 to 
0.041), after the first and the second year (p = 0.017 and 0.020), 
and at any time during the follow-up (p = 0.017).
Patients with MRI activity in the first seven years apparen-
tly had fewer relapses prior to treatment (p = 0.041).
Correlations with BAb and NAb status
For BAb, a significant correlation with NEDA was found: 
patients with persistent BAb were more likely to experience 
disease activity after year 4 [p = 0.014, RR 7.333 (95% CI 
0.511 to 105.267), p for RR 0.143 and year 5 (p = 0.049, RR 
6.75 (95% CI 0.468 to 97.264), p for RR 0.161]. There were no 
other associations between BAb status and NEDA, relapses, 
progression, MRI activity, number of relapses, or EDSS score 
at any time period.
Table 3. Proportion of patients with positive and negative anti-IFNβ antibody status
All Female Male
BAb: All tested 97 74 23
BAb (+) at any time 95 (98%) 72 (97%) 23 (100%)
transient BAb (+) 7 (7%) 5 (7%) 2 (9%)
persistent BAb (+) 88 (91%) 67 (91%) 21 (91%)
BAb (-) 2 (2%) 2 (3%) 0 (0%)
baseline BAb (+) 66 of 72 (92%) 47 of 53 (89%) 19 of 19 (100%)
NAb: All tested 77 58 19
NAb (+) at any time 68 (87%) 50 (84%) 18 (95%)
transient NAb (+) 1 (1%) 1 (2%) 0 (0%)
persistent NAb (+) 67 (86%) 49 (84%) 18 (95%)
NAb (-) 9 (12%) 8 (14%) 1 (5%)
baseline NAb (+) 9 of 72 (12.5%) 8 of 53 (15%) 1 of 19 (5%)
BAb — binding antibodies; NAb — neutralising antibodies 
No difference in baseline characteristics was found between BAb (+) and BAb (-) or between NAb (+) and NAb (-) cases
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Table 4. Anti–IFNβ antibody prevalence: by samples and cumulative (with assumption of no change from last known result for missing data)
BAb
Samples Baseline 1 month 3 months 6 months 12 months 24 months 36 months
All 72 30 3 14 4 49 28
Positive 66 14 0 4 1 45 28
Negative 6 16 3 10 3 3 0
% positive 91.7% 46.7% 0.0% 28.6% 25.0% 91.8% 100.0%
% negative 8.3% 53.3% 100.0% 71.4% 75.0% 6.1% 0.0%
NAb
Samples Baseline 1 month 3 months 6 months 12 months 24 months 36 months
All 72 30 3 14 4 49 28
Positive 9 3 0 3 0 45 22
Negative 63 27 3 11 4 3 6
% positive 12.5% 10.0% 0.0% 21.4% 0.0% 91.8% 78.6%
% negative 87.5% 90.0% 100.0% 78.6% 100.0% 6.1% 21.4%
Cases BAb
Cumulative Baseline 1 month 3 months 6 months 12 months 24 months 36 months
Positive 66 67 65 65 64 73 87
Negative 31 30 32 32 33 24 10
% positive 68.0% 69.1% 67.0% 67.0% 66.0% 75.3% 89.7%
% negative 32.0% 30.9% 33.0% 33.0% 34.0% 24.7% 10.3%
Cases NAb
Cumulative Baseline 1 month 3 months 6 months 12 months 24 months 36 months
Positive 9 11 11 13 12 55 67
Negative 68 66 66 64 65 22 10
% positive 11.7% 14.3% 14.3% 16.9% 15.6% 71.4% 87.0%
% negative 88.3% 85.7% 85.7% 83.1% 84.4% 28.6% 13.0%
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Figure 1. Proportion of patients with no disease activity (according to NEDA-3 criteria) and patients with relapses, progression and MRI 
activity in subsequent years
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Figure 2. Proportion of patients with no disease activity (according to NEDA-3 criteria), relapses, progression and MRI activity over time
No association was found between NAb and any form of 
disease activity.
Excluding patients with baseline positivity and with unk-
nown baseline status, attempting to distinguish between the 
antibodies present at baseline and those developed after drug 
exposure was impossible due to the small sample size [i.e. 
no BAb (-) cases were left, three baseline NAb (-) patients]. 
Therefore, only patients with known baseline positivity were 
excluded. A trend for higher disease activity was found for NAb 
(+) in the first year (p = 0.098), and for the first two years (p = 
0.069). In addition, a trend for higher disease activity in BAb 
(+) cases after years 4 and 5 (both with p = 0.061) re-emerged.
After moving the baseline positive patients to antibody 
negative groups, NAb (+) was associated with a higher risk of 
disease activity in the first two [p = 0.019, RR 3.724 (95% CI 
0.990 to 14.017), p for RR 0.052] and three years [p = 0.041, 
RR 2.210 (95% CI 0.928 to 5,260), p for RR 0.073], as well as 
in the entire follow up [p = 0.044, RR 1.575 (95% CI 0.930 to 
2.668), p for RR 0.091]. It also correlated with MRI activity 
in the first three years [p = 0.043, RR 6.938 (95% CI 0.458 to 
105.035), p for RR 0.162].
In logistic regression analysis, this modified NAb (+) 
status was a significant independent variable in enter method 
and was retained as the only significant variable in forward 
method in models for disease activity within the first two 
years of treatment.
When considering baseline BAb (+) as BAb (-), BAb (+) 
was associated with a higher risk of treatment discontinuation, 
of NEDA-3 loss after the first and the second year, a lower risk 
of relapse in year 6 although higher in year 4, a higher risk 
of disease progression in year 6, but again a lower risk after 
the first and the second year and in the follow-up as a whole. 
BAb (+) also showed less MRI activity after the first year and 
in the entire observation.
Comparing patients with and without baseline BAb and 
NAb [BAb0 (+) and BAb0 (-), NAb0 (+) and NAb0 (-)], regar-
dless of subsequent antibody status, NAb0 (+) was associated 
with a lower risk of disease activity in the first three years (p 
= 0.017, RR = 0.2239, 95% CI: 0.03611 to 1.3890, p for RR = 
0.1080). For baseline BAb, no significant associations were 
found in direct comparisons, but they remained the only 
significant variable in a forward model for relapse activity in 
the first year of treatment, where the absence of baseline BAb 
increased the likelihood of relapses (Tab. 5). 
Logistic regression
For each time period and activity measure, logistic re-
gression models were computed with combinations of BAb 
and NAb, persistent BAb and Nab, and baseline clinical 
characteristics.
Neither BAb nor NAb status, persistent or not, was re-
tained as a significant independent contributor. Conversely, 
pre-treatment EDSS and relapses were abundantly included 
in models predicting progression, while several relapse and 
MRI activity models contained age, treatment delay, or time to 
second relapse. Only two models reached significant goodness 
of fit, one including NAb, the other persistent NAb (outcome: 
progression after third year, both with p = 0.015 and Hosmer-
-Lemeshow p < 0.001) (Tab. 6). For these variable sets, in 
forward, backward and stepwise method, only pre-treatment 
EDSS and relapses were retained.
Discussion
The abundance of NAb and BAb positivity before treatment 
is the most surprising finding of our study. Previous works have 
reported naturally occurring BAb and NAb in less than 1% of 
the healthy population and treatment-naive MS patients [1]. 
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Table 5. Logistic regression analysis: relapses in the first year of treatment
Variable Coefficient Standard error Wald’s c2 p
Baseline Bab (—) 1.974 0.977 4.084 0.043
Constant -1.569   
Table 6. Logistic regression analysis: progression after third year of treatment
Variable Coefficient Standard error Wald’s c2 p
NAb (+) / persistent  
NAb (+)*
17.226 2,881.824 < 0.001 0.995
Age at first relapse, years -0.001 0.056 < 0.001 0.983
Gender -0.743 1.182 0.395 0.530
Time to second relapse, months 0.041 0.063 0.424 0.515
Time to treatment start, months -0.063 0.053 1.437 0.230
Baseline EDSS score 2.481 1.146 4.691 0.030
Number of relapses prior to 
treatment
1.490 0.716 4.330 0.037
Constant -23.075   
*the models were otherwise identical
On the other hand, NAb developed in 11% of patients in the 
placebo group of a stage III clinical trial of IFNβ-1b [2]. It is 
understandable that positivity prevalence depends to a great 
extent on the assay’s sensitivity and cut-off thresholds [1, 24]. 
Therefore these pre-treatment antibodies probably represent 
naturally occurring, nonspecific antibodies of very low affinity 
and variable IFN neutralising activity. Alternatively, this could 
potentially be caused by a methodological issue (i.e. sample 
contamination) or, less likely, a cross-reactivity with an antigen 
commonly encountered in the Polish population.
It is plausible that a  different kind of anti-interferon 
antibodies develops in response to drug exposure and under-
goes gradual maturation, eventually gaining IFN neutralising 
properties.
Removal of the baseline NAb-positive cases from the 
analysis brought a  trend towards more disease activity in 
NAb (+) and, curiously, BAb (+) patients, supporting the 
hypothesis that the baseline and aquired antibodies represent 
two different phenomenons. An assignment switch involving 
moving baseline positive patients to the antibody negative 
groups revealed an association between early disease activity 
and NAb positivity, not unlike the previous evidence [2, 6–11]. 
An analogous grouping shift changed BAb correlations greatly, 
with contradictory associations with disease activity. 
These inconsistent results suggest that the co-occurrence 
of unspecific and specific binding antibodies is probably 
common, and renders this analysis invalid.
Interestingly, pre-treatment antibodies predicted a more 
indolent course in the first three years of treatment. This 
resembles the observations from pivotal trials of IFNβ in 
MS [2, 25, 26], where patients who were to develop NAb in 
later observations had lower relapse rates in the first six or 
12 months of treatment. This was thought to be caused by 
low-affinity anti-IFN antibodies that could initially prolong 
the drug’s half-life, but would eventually develop into harmful, 
detectable NAb due to affinity maturation [24]. 
We are aware of our study’s  limitations. Due to the 
strict eligibility criteria for the Polish MS treatment pro-
gramme, patients with low pre-treatment disease activity 
were preferentially included. This may explain why the 
study cohort experienced a relatively benign disease course. 
However, disease activity statistics were similar in other 
recently described populations [27]. Thirty-five percent 
of cases were lost after the third year of treatment due 
to the programme duration limit, regardless of response, 
while many continued treatment despite sustained disease 
activity (20–30% non-NEDA in each year), as second-line 
therapeutics were either not yet registered or out of reach 
due to programme criteria. 
Because of poor patient co-operation and technical limi-
tations, a significant number of scheduled samples were not 
collected. 
Conclusions and future directions
In our RRMS cohort, we observed a high prevalence of 
naturally occurring anti-IFNβ BAb and NAb.
Exclusion of the NAb0 (+) cases brought results remi-
niscent of previous ones, with a trend towards more disease 
activity in NAb (+) and, notably, BAb (+) patients. An assign-
ment switch (moving NAb0 (+) and BAb0 (+) patients to the 
NAb (-) and BAb (-) groups) revealed an association between 
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early disease activity and NAb, consistent with previously 
published research.
Patients with baseline positivity in BAb or NAb expe-
rienced less disease activity in the first one or three years of 
treatment.
We propose that two types of anti-interferon antibodies 
were detected by our assays: specific, drug-induced antibodies 
and also low-affinity, naturally occurring antibodies. The 
naturally occurring antibodies are beneficial or reflect an 
advantageous immune state. Drug-induced antibodies, once 
they reach a certain neutralising activity, inhibit IFNβ activity 
and cause loss of drug efficacy.
Our findings require confirmation in further studies. The 
prevalence and specificity of low-affinity antibodies should 
be determined. Also, a titre or anti-IFN activity threshold of 
predictive significance should be established if possible.
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